Lijenta 5

Linagliptin
5 mg Tablet
Description:

Lijenta 5 is an inhibitor of DPP-4 , an enzyme that degrades the incretin hormones GLP-1 and GIP. Thus, Linagliptin increases the concentratins of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucangon from pancreatic alpha cells in the circulation.Thus it improves glycemic control in patients with type 2 diabetes mellitus.


  • Composition

    Each film coated tablet contains Linagliptin INN 5 mg.
  • Indication

    Lijenta 5 is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults. As monotherapy-in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance or contraindicated due to renal impairment. As combination therapy-in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control-in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
  • Dosage & Administration

    5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulfonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.

    Patients with renal impairment: no dose adjustment required. Linagliptin can be taken with or without a meal at any time of the day.
  • Contraindication

    Hypersensitivity to the active substance or to any of the excipients.
  • Precaution

    Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
  • Side Effects

    There may be hypoglycaemia, nasopharyngitis, cough and pancreatitis in combination with metformin and sulfonylurea.
  • Drug Interaction

    Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. The risk for clinically meaningful interactions by other medicinal products on linagliptin is low and in clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives.
  • Overdose

  • Pregnancy & Lactation

    Avoid use during pregnancy. A risk to the breast-fed child cannot be excluded.
  • Storage Condition

    Keep in a dry place away from light and heat. Keep out of the reach of children.
  • How Supplied

    Each box contains 20 tablets in Alu-Alu blister pack.